Sun Pharmaceutical Industries Ltd 2023 SR
The report details Sun Pharma's ESG performance for FY23, highlighting a 7% reduction in Scope 1 and 2 emissions and a 21% reduction in water consumption since 2020. The company became a signatory to the UN Global Compact and initiated climate risk assessments aligned with TCFD. Key achievements include sourcing 32% of energy from renewable sources and attaining Great Place to Work certification. Sun Pharma also invested ₹23.7 billion in R&D and reached over 1 million people through CSR initiatives focused on healthcare and education.
Company: Sun Pharmaceutical Industries Ltd
Sector: Manufacturing
Country: India
Year: 2023
Type: SR
Pages: 108
Back to company
Sun Pharmaceutical Industries Ltd
Sustainability Report
The report details Sun Pharma's ESG performance for FY23, highlighting a 7% reduction in Scope 1 and 2 emissions and a 21% reduction in water consumption since 2020. The company became a signatory to the UN Global Compact and initiated climate risk assessments aligned with TCFD. Key achievements include sourcing 32% of energy from renewable sources and attaining Great Place to Work certification. Sun Pharma also invested ₹23.7 billion in R&D and reached over 1 million people through CSR initiatives focused on healthcare and education.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2023
Reporting Period
Apr 1, 2022 - Mar 31, 2023
Fiscal Year
2023
Published
Aug 17, 2023
Type
Sustainability Report
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
Assurance
Assurance Provider
Assurance Standard
Sustainable Development Goals
Other Standards
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Scope 3:
Energy Consumption
Renewable Energy
Water Consumption
Total Waste
Women on Board
Women in Management
Workplace Fatalities
Employees